I trained as a journalist and worked at news organizations where all the reporters wanted to cover politics and crime.
Kathryn Metcalfe
Vice President, Corporate Reputation and Policy Communications, Pfizer
I trained as a journalist and worked at news organizations where all the reporters wanted to cover politics and crime. But then I had an epiphany: As a reporter, you had to wait for news to happen. As communicator on the inside of a company, you get to make the news happen. I was hooked on public relations from that moment on. Now, I am in a newly created role that combines corporate reputation and public policy communications. I am responsible for making Pfizer's reputation a valuable asset, shaping our company's public image among multiple stakeholders.
I believe many leaders in this industry miss the opportunity to innovate with the people they lead. Listening to employees can be a powerful engine of innovation, and launches a virtuous cycle where success breeds greater success. I'd point to the program Pfizer just announced to provide free medicines to those in the United States who are newly unemployed and have lost their health coverage. It's a program that fills a vast unmet need and helps advance what I want Pfizer—and all of pharma—to stand for. The response has been incredible—people were even cheering in airports when word about the program broke on cable news.
American business is at an inflection point, with new business models taking shape and a class of younger entrepreneurs now maturing into larger leadership roles. The flip side of the youth movement is that CEOs in pharma and elsewhere are having shorter tenures. To be successful over the long term, any management team must balance both youth and experience and be diverse in background and thought. But I believe the core mission of our companies will endure. We have a good chance of seeing a new "golden age of medicine," when we can free people from our most feared diseases, including Alzheimer's, cancer, and infection.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.